Next Article in Journal
Tailoring the Evidence for Exercise Oncology within Breast Cancer Care
Previous Article in Journal
Pretreatment Modified Albumin–Bilirubin Grade Is an Important Predictive Factor Associated with the Therapeutic Response and the Continuation of Atezolizumab plus Bevacizumab Combination Therapy for Patients with Unresectable Hepatocellular Carcinoma
 
 
Article

Article Versions Notes

Curr. Oncol. 2022, 29(7), 4811-4826; https://doi.org/10.3390/curroncol29070382
Action Date Notes Link
article xml file uploaded 8 July 2022 16:55 CEST Original file -
article xml uploaded. 8 July 2022 16:55 CEST Update https://www.mdpi.com/1718-7729/29/7/382/xml
article pdf uploaded. 8 July 2022 16:55 CEST Version of Record https://www.mdpi.com/1718-7729/29/7/382/pdf
article supplementary file uploaded. 8 July 2022 16:55 CEST - https://www.mdpi.com/1718-7729/29/7/382#supplementary
article html file updated 8 July 2022 16:56 CEST Original file -
article html file updated 13 August 2022 00:55 CEST Update https://www.mdpi.com/1718-7729/29/7/382/html
Back to TopTop